Strategic Advocates’s 10x Genomics TXG Stock Holding History

Strategic Advocates’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-2	Closed	-$23	–	651
2025 Q3	$23	Buy	+2	New	+$26	﹤0.01%	604

Other funds holding TXG

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

QCM

Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Strategic Advocates's TXG Position: Q4 2025 in Review

Strategic Advocates sold out of 10x Genomics (TXG) in Q4 2025, closing a stake of 2 shares — an estimated $23 sold.

Strategic Advocates first reported a position in TXG in Q3 2025 and held it in 1 quarter. The position peaked at $23 in Q3 2025. 322 funds tracked by Wall St. Rank hold TXG as of Q4 2025.

Strategic Advocates reported no remaining 10x Genomics position as of Q4 2025 after selling out during the quarter.
Strategic Advocates sold 2 10x Genomics shares in Q4 2025, an estimated $23.
Strategic Advocates first reported a position in 10x Genomics in Q3 2025 and held it in 1 quarter.
Strategic Advocates's 10x Genomics position peaked at $23 in Q3 2025.
322 funds tracked by Wall St. Rank held 10x Genomics as of Q4 2025.

Based on Strategic Advocates's 13F filing for Q4 2025, filed 11 Feb 2026.